ImmunityBio (IBRX) Return on Capital Employed (2015 - 2026)
ImmunityBio's (IBRX) quarterly Return on Capital Employed came in at 51.63% in Q1 2026, up 5493.0% year-on-year from 0.92% in Q1 2025, and up 9.53% on a QoQ basis from 57.06% in Q4 2025.
ImmunityBio (IBRX) Return on Capital Employed (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 12 years of Return on Capital Employed data on file, last reported at 51.63% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 5493.0% year-over-year to 51.63% in Q1 2026; TTM through Mar 2026 was 51.63%, a 5493.0% increase from a year earlier, with the FY2025 full-year figure at 67.26%, up 2128.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 51.63%, up from 57.06% in the prior quarter.
- Over the last five years, Return on Capital Employed for IBRX reached as high as 1489.88% in Q2 2022 and fell as low as 704.86% in Q1 2022.
- Historically, Return on Capital Employed has averaged 11.95% across 5 years, with a median of 88.32% in 2023.
- Across the five-year window, Return on Capital Employed surged 166516 bps in 2022 and tumbled 136413 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 245.3% in 2022, then sank by 136 bps to 88.32% in 2023, then slipped by 22 bps to 107.96% in 2024, then jumped by 47 bps to 57.06% in 2025, then gained by 10 bps to 51.63% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 51.63% in Q1 2026, 57.06% in Q4 2025, and 64.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | ImmunityBio | 7.60 Bn | 7.22 Bn | 43.97 Mn | -51.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.63% |
| Dec 31, 2025 | -57.06% |
| Sep 30, 2025 | -64.64% |
| Jun 30, 2025 | -94.41% |
| Mar 31, 2025 | -106.55% |
| Dec 31, 2024 | -107.96% |
| Sep 30, 2024 | -104.86% |
| Jun 30, 2024 | -99.91% |
| Mar 31, 2024 | -86.73% |
| Dec 31, 2023 | -88.32% |
| Sep 30, 2023 | -133.25% |
| Jun 30, 2023 | 125.75% |
| Mar 31, 2023 | 173.01% |
| Dec 31, 2022 | 245.30% |
| Sep 30, 2022 | -130.69% |
| Jun 30, 2022 | 1,489.88% |
| Mar 31, 2022 | -704.86% |
| Dec 31, 2021 | 1,208.51% |
| Sep 30, 2021 | -170.89% |
| Jun 30, 2021 | -175.27% |